Search results
Showing 376 to 390 of 464 results for blood monitoring
The RhinoChill intranasal cooling system for reducing temperature after cardiac arrest (MIB4)
NICE has developed a Medtech Innovation Briefing (MIB) on the RhinoChill intranasal cooling system
Evidence-based recommendations on zanidatamab (Ziihera) for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment in adults.
Show all sections
Brodalumab for treating moderate to severe plaque psoriasis (TA511)
Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults.
Contrast-enhanced spectral mammography for breast cancer (MIB304)
NICE has developed a medtech innovation briefing (MIB) on contrast-enhanced spectral mammography for breast cancer .
Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic hormone-relapsed prostate cancer in adults who have had treatment with docetaxel-containing chemotherapy.
Ambu aScope 4 Broncho for routine diagnostic and therapeutic bronchoscopy (MIB314)
NICE has developed a medtech innovation briefing (MIB) on Ambu aScope 4 Broncho for routine diagnostic and therapeutic bronchoscopy .
User guide for the cost comparison company evidence submission template (PMG32)
This user guide describes how to submit evidence to NICE when a cost-comparison case is made as part of the fast track technology appraisal process. It explains what information NICE requires and the format in which it should be presented
FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care (HTG682)
Evidence-based recommendations on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care.
First disease-modifying therapy for NHS use to delay the onset of type 1 diabetes recommended
A first-of-its-kind therapy that can delay the onset of type 1 diabetes for up to 3 years is to be made available on the NHS.
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)
Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy.
Evidence-based recommendations on peginterferon alfa (Pegasys; ViraferonPeg) and ribavirin (Copegus) for treating chronic hepatitis C in children and young people.
Evidence-based recommendations on ranibizumab (Lucentis) for treating visual impairment caused by macular oedema secondary to retinal vein occlusion in adults.
Physical activity: for NHS staff, patients and carers (QS84)
This quality standard covers encouraging physical activity in people of all ages who are in contact with the NHS, including staff, patients and carers. It describes high-quality care in priority areas for improvement.
View quality statements for QS84Show all sections
Sections for QS84
- Quality statements
- Quality statement 1: Advice for adults during NHS Health Checks
- Quality statement 2: Advice for parents or carers as part of the Healthy Child Programme 2-year review
- Quality statement 3: Advice for parents or carers as part of the National Child Measurement Programme
- Quality statement 4: Implementing a physical activity programme for employees in NHS organisations
- Update information
- About this quality standard
Evidence-based recommendations on avacopan (Tavneos) for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis in adults.
High-sensitivity troponin tests for the early rule out of NSTEMI (HTG552)
Evidence-based recommendations on high-sensitivity troponin tests for the early rule out of NSTEMI (non-ST-segment elevation myocardial infarction).